300347 泰格醫藥
按盤價 
49.850 -0.930 (-1.831%)
49.850 -0.930 (-1.831%) | 2026/06 - 中期 人民幣(K¥) | 與去年同期 比較 | 2025/12 人民幣(K¥) | 2024/12 人民幣(K¥) | 2023/12 人民幣(K¥) | 2022/12 人民幣(K¥) | ||
| 營業總收入 | 3,707,560 | 14.06% | 6,832,801 | 6,603,120 | 7,384,039 | 7,085,471 | |
| 減：營業總成本 | 3,348,892 | 13.82% | 6,312,645 | 5,610,048 | 5,554,125 | 5,156,544 | |
| 其中:營業成本 | 2,687,044 | 18.24% | 4,959,606 | 4,361,107 | 4,535,511 | 4,277,008 | |
| 財務費用 | 42,285 | -33.18% | 99,902 | 38,067 | (108,324) | (158,124) | |
| 資產減值損失 | (3,599) | -16.21% | (38,961) | 1,255 | (29,725) | (2,416) | |
| 公允價值變動收益 | (443,324) | 394.54% | 42,256 | (501,688) | 352,771 | 535,857 | |
| 投資收益 | (2,432) | -101.04% | 433,816 | 166,642 | 338,175 | 102,751 | |
| 其中：對聯營企業和合營企業的投資收益 | 21,662 | -86.98% | 198,507 | 31,271 | 105,183 | 39,763 | |
| 營業利潤 | (78,649) | -117.70% | 1,009,420 | 664,419 | 2,486,941 | 2,582,399 | |
| 利潤總額 | (80,215) | -118.12% | 1,003,215 | 664,462 | 2,488,533 | 2,585,377 | |
| 減：所得稅費用 | 105,256 | 31.80% | 198,159 | 216,630 | 338,606 | 313,652 | |
| 淨利潤 | (185,471) | -151.12% | 805,056 | 447,831 | 2,149,927 | 2,271,725 | |
| 減：非控股權益 | 227,688 | -1,210.20% | (82,834) | 42,688 | 125,077 | 265,173 | |
| 股東淨利潤 | (413,160) | -207.78% | 887,890 | 405,143 | 2,024,850 | 2,006,552 | |
市場價值指標 | |||||||
| 每股收益 (元) * | -0.480 | -206.67% | 1.040 | 0.470 | 2.340 | 2.320 | |
| 每股派息 (元) * | -- | -- | 0.126 | 0.300 | 0.568 | 0.550 | |
| 每股淨資產 (元) * | 22.621 | -5.10% | 24.342 | 23.898 | 24.102 | 22.447 | |
| 審計意見 # | -- | 标准的无保留意见 | 标准的无保留意见 | 标准的无保留意见 | 标准的无保留意见 | ||
| 備註： | *未調整數據 |
| #只提供簡體內容 | |
| 報價延遲最少15分鐘，資料更新時間為 28/08/2026 16:30 |
- 經濟通
- 強化版MQ
- 強化版TQ
- 財曆
- Mobile
Web
